Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.
Samuel Dagogo-JackRobert FrederichJie LiuChristopher P CannonHarry ShiDavid Z I CherneyFrancesco CosentinoUrszula MasiukiewiczIra GantzRichard E PratleyPublished in: The Journal of clinical endocrinology and metabolism (2023)
In VERTIS CV patients, ertugliflozin reduced the likelihood of insulin initiation, delayed the time to insulin initiation by up to ∼1.8 years, and reduced insulin dose requirements vs placebo, without increasing hypoglycemia events.